Back to Search
Start Over
Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy.
- Source :
-
Cells [Cells] 2021 Mar 17; Vol. 10 (3). Date of Electronic Publication: 2021 Mar 17. - Publication Year :
- 2021
-
Abstract
- Glucose-regulated protein 94 (GRP94) is an endoplasmic reticulum (ER)-resident member of the heat shock protein 90 (HSP90) family. In physiological conditions, it plays a vital role in regulating biological functions, including chaperoning cellular proteins in the ER lumen, maintaining calcium homeostasis, and modulating immune system function. Recently, several reports have shown the functional role and clinical relevance of GRP94 overexpression in the progression and metastasis of several cancers. Therefore, the current review highlights GRP94's physiological and pathophysiological roles in normal and cancer cells. Additionally, the unmet medical needs of small chemical inhibitors and the current development status of monoclonal antibodies specifically targeting GRP94 will be discussed to emphasize the importance of cell surface GRP94 as an emerging therapeutic target in monoclonal antibody therapy for cancer.
- Subjects :
- Cell Membrane drug effects
Cell Membrane metabolism
Endoplasmic Reticulum drug effects
Endoplasmic Reticulum metabolism
Humans
Membrane Glycoproteins immunology
Membrane Glycoproteins metabolism
Molecular Chaperones drug effects
Molecular Chaperones metabolism
Neoplasms metabolism
Antibodies, Monoclonal therapeutic use
Antineoplastic Agents, Immunological therapeutic use
Cell Membrane immunology
Membrane Glycoproteins drug effects
Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 2073-4409
- Volume :
- 10
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Cells
- Publication Type :
- Academic Journal
- Accession number :
- 33802964
- Full Text :
- https://doi.org/10.3390/cells10030670